Microsclerotherapy Market Size, Share, and COVID-19 Impact Analysis By Product Type (Detergents (Polidocanol, Sodium Tetradecyl Sulfate, and Ethanolamine Oleate), Osmotic Agents (Hypertonic Glucose and Hypertonic Sodium Chloride Solution), and Chemical Irritants (Chromated Glycerin and Polyiodinated Iodine), and By End-User (Hospitals and ASCs, Dermatology Clinics, and Others), and Regional Forecast, 2025-2032

Microsclerotherapy is a minimally invasive procedure that is used for the treatment of telangiectasia. It is a condition where small widened blood vessels are formed on the skin causing thread-like red lines or patterns. It is caused due to multiple factors such as aging, pregnancy, rosacea varicose veins, and overexposure to sunlight.

The procedure involves injecting of a sclerosing agent into the affected veins thus causing the closing of the vessel. This procedure is said to be effective in comparison to other traditional treatments such as faster recovery time, lower complication risk and improve cosmetic results. Furthermore, the growing prevalence of varicose veins and other certain lifestyle factors are a few of the reasons for the growing incidence of telangiectasia, thus increasing the adoption of microsclerotherapy among individuals.

• For instance, according to an article published in the National Library of Medicine in 2022, an epidemiological study mentioned that in the U.S. among the 40-80 year age group, 11.0 million men and 22.0 million women have varicose veins.

Furthermore, the growing adoption of microsclerotherapy procedures among individuals has led several pharmaceutical and medical devices company to introduce new sclerosants in the market, thus driving market growth.

Impact of COVID-19 on the Microsclerotherapy Market 

The COVID-19 pandemic created significant disruptions in the functioning of healthcare institutions worldwide. The lockdown and COVID-19 restrictions postponed all elective procedures including microsclerotherapy. Due to the lack of availability of anesthetists during COVID, the number of procedures witnessed a staggering decline during this period. Thus, the microsclerotherapy market witnessed a significant decline during the pandemic.

• For instance, according to The Society for Vascular Surgery Patients Safety Organization, in May 2020, approximately 74% of physicians adopted restrictive operating policies for urgent and emergency cases only.

As the COVID-19 pandemic became a public health crisis, lockdown restrictions were imposed across the country which led many people to begin living a sedentary lifestyle, thus contributing to the development of varicose veins during the period.

In 2021, post the pandemic, the number of procedures increased as healthcare institutions slowly began to conduct minimally invasive procedures again. Thus leading to the recovery of the market.

Key Insights: 

• New Product launches, By Key Players.
• Key Industry developments- Partnerships, Mergers, and Acquisitions.
• Overview: Technological Advancements in the Market.
• Impact of COVID-19 on AI in Genomics Market.

Analysis by End User:

Based on Product type, the market is bifurcated into detergents, osmotic agents, and chemical irritants. The detergents segment is estimated to hold the largest share of the market. Detergents like polidocanol and sodium tetradecyl sulfate are widely used for the treatment for spider veins. The products can be used in various concentrations ranging from 0.05% to 0.5%. Factors like high efficiency and lower risk of side effects majorly contribute to the segment’s growth. Regular approval for detergents by regulatory bodies is also one of the major factors for the wide adoption of detergents for microsclerotherapy. 

Furthermore, many studies conducted to test the toxic effect of detergent sclerosing agents state that the addition of detergents such as polidocanol, sodium tetradecyl sulfate, and ethanolamine oleate to citrated plasma did not cause clotting, thus resulting in wider adoption of the agent.

Regional Analysis: 

To gain extensive insights into the market, Download for Customization

North America market holds the largest share in the market due to the presence of major players in the region. Furthermore, the increasing number of research and development initiatives and technological advancements in venous diseases also contribute to the growth of the market in the region.

Moreover, the growing prevalence of varicose veins and spider veins in the region along with the awareness regarding the adoption of minimally invasive surgeries such as microsclerotherapy also fuel the growth of the market.

• For instance, according to the Canadian Society of Vascular Surgery, 20.0% of the adult population in Canada suffer from varicose veins.

Asia Pacific is expected to show lucrative growth in the forecast period. This is due to the increasing number of Geriatric population and sedentary lifestyle in developing countries such as India and China.

• For instance, according to the World Economic Forum, the population of people over the age of 60 or above in China has reached 267.0 million or 18.9% of the total population. Furthermore, it is estimated that this may rise to one-third of the total population before 2050.

These factors have led to individuals suffering from varicose veins and spider veins. The increasing prevalence is leading to the adoption of minimally invasive procedures such as microsclerotherapy, therefore fueling the market growth.

Key Players: 

The report will include the profiles of key players such as Medtronic, STD Pharmaceutical Products, Methapharm, Inc., QOL Medical, LLC. Chemische Fabrik Kreussler & Co. GmbH, Boston Scientific Corporation, and Viatris Inc.

Segmentation:

Key Industry Developments:

• June 2022: I-VASC announced its CE-marked product VELEX system which is used for the treatment of CVI, a condition that includes varicose veins announced that the product has entered clinical use.
• November 2020: Vascular Barcelona Devices, SL (VB Devices) announced the CE Mark approval for its Varixio Pod Air Product, which is used for the automation of the preparation of foam for sclerotherapy of varicose veins.
• December 2019: Leucadia Pharmaceuticals and the commercial sales arm of Custopharm, Inc., announced the launch of the only FDA-approved Sodium Tetradecyl Sulfate (STS) generic.